key: cord-0945017-ei9qj5fi authors: Ngeow, K. C.; Xie, C.; Teo, A. K. J.; Hsu, L. Y.; Tan, M.-H.; Choudhury, Y. title: MassMark: A Highly Scalable Multiplex NGS-based Method for High-Throughput, Accurate and Sensitive Detection of SARS-CoV-2 for Mass Testing date: 2021-01-09 journal: nan DOI: 10.1101/2021.01.08.20249017 sha: 80e4e6609fedf47c778736e3027a77af85cfdbc6 doc_id: 945017 cord_uid: ei9qj5fi Mass testing has been proposed as a strategy to address and contain the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We have developed MassMark, a novel and highly scalable multiplex method that employs next generation sequencing for high-throughput, accurate and sensitive detection of SARS-CoV-2, while minimizing handling complexity and resources by utilizing a serial pooling strategy to accommodate over 9,000 samples per workflow. Analytical validation showed that MassMark was able to detect SARS-CoV-2 RNA down to a level of 100 copies per reaction. We evaluated the clinical performance of MassMark in a simulated screening testing with 22 characterized samples from three different sources (nasopharyngeal swabs, nasal swabs and saliva), comprising of 12 SARS-CoV-2 positive samples with mid to late Ct values (range: 22.98-32.72) and 10 negative samples. There was one false negative and no false positives, giving an overall sensitivity and specificity of 91.67% and 100% respectively, when compared against an optimized RT-PCR test with a target size within 70 bp (CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel). Introduction that contributes to viral transmission 18, 19 but are difficult to identify with existing symptombased detection protocols. While SARS-CoV-2 diagnostic testing capacity has increased considerably worldwide since the start of the pandemic, there is still a vast and significant gap between actual testing capacity and benchmark numbers needed to suppress the spread of the SARS-CoV-2 virus 1,20 . Inadequate testing capacity has led to testing backlogs and increased turnaround times 21 , hampering efforts to curtail infections 22 . Other than the gold standard RT-PCR method, alternative testing modalities will need to be introduced to overcome logistical bottlenecks and increase testing throughput in order for mass testing to become a feasible reality. Here, we describe MassMark, a novel method to scale-up SARS-CoV-2 diagnostic testing capacity via the use of massively parallel next-generation sequencing (NGS). Like other proposed NGS-based approaches for SARS-CoV-2 diagnostics [23] [24] [25] [26] [27] , MassMark utilizes molecular barcodes to identify positive cases by incorporating a unique, predetermined combination of index sequences to amplify the viral RNA present in a positive sample, while samples negative for SARS-CoV-2 do not get amplified. The molecular barcode tagging is achieved in two steps with serial reduction in handling complexity, using only two sets of 96 unique index sequences for over 9000 samples. The use of molecular barcodes allows thousands of patient samples to be sequenced in parallel in a single NGS run, after which demultiplexing is performed via the barcode sequences to retrieve the identity of samples that are positive for SARS-CoV-2. We demonstrate that MassMark can be used for highly sensitive and specific detection of extracted SARS-CoV-2 RNA from nasopharyngeal swabs, nasal swabs and saliva. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. ; https://doi.org/10.1101/2021.01.08.20249017 doi: medRxiv preprint The MassMark method (Fig 1A) consists of two serial rounds of barcoding with uniquely indexed primers and sample pooling. In the first step, extracted viral RNA is specifically converted to complementary DNA (cDNA) via reverse transcription (RT) at three target regions of the SARS-CoV-2 virus with three separate barcoding RT primers. Each barcoding RT primer consists of a region of homology to its specific target region of SARS CoV-2 and a predetermined 10-bp index sequence corresponding to the sample well position in a 96-well plate. For each well, the three RT primers carry the same 10-bp index sequence. During the RT step, individual samples are labelled with a unique sample index (well barcode). A sample that is negative for SARS-CoV-2 will fail to incorporate the corresponding index sequences. Products of cDNA synthesis from each 96-well plate are then combined, concentrated and purified together in a single pool. Each cDNA pool originating from a single 96-well plate is then subjected to a limited PCR cycle with a second set of three barcoding primers, each consisting of a region of homology to its specific target region of SARS CoV-2 and a predetermined 10-bp index sequence corresponding to the plate identity. The limited PCR converts the products of the first step of cDNA synthesis to double-stranded DNA products. Importantly, the limited PCR step additionally labels each individual sample with a second index (plate barcode) common to all samples originating from the same RT plate. Together with the first sample index (well barcode) introduced during RT, the addition of the second sample index means that each sample will be in possession of a unique dual-index combination that allows for subsequent demultiplexing. Products of limited PCR (up to 96) are combined, concentrated and purified together, resulting in a single pool of pools that represents SARS-CoV-2 amplicon sequences from up to 96x96 samples. This double-stranded 96x96 DNA pool then undergoes a final PCR amplification step to introduce adapters compatible with Illumina sequencing, and, optionally, to attach additional . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. ; https://doi.org/10.1101/2021.01.08.20249017 doi: medRxiv preprint library indexes to allow multiple 96x96 pools to be multiplexed in the same sequencing run ( Fig 1B) . The final amplified library is sequenced, following which sequencing reads corresponding to each amplicon are identified by their expected SARS-CoV-2 sequence and are assigned to a starting sample by the identifiable, unique combination of well and plate barcodes associated with each amplicon that was finally represented in the sequencing library. An external spike-in control RNA is included in every well as a process control. We verified that all three amplicons A, B and C were amplified in positive control samples comprised of synthetic SARS-CoV-2 RNA, diluted to known copy numbers with nuclease-free water. We observed a linear relationship between sequencing read counts and the amount of RNA input from approximately 100 to 50,000 copies per reaction, for all three amplicons ( Fig 2) . To determine the analytical limit of detection for MassMark, we repeated the protocol on 96 contrived samples comprising of 0 copies (n=56), 100 copies (n=20) and 250 copies (n=20) of synthetic SARS-CoV-2 RNA (Fig 3) . At 100 input copies of SARS-CoV-2, reads above noise level (i.e. above read counts for 0-copy samples, in theory expected to be zero) corresponding to Amplicons A, B and C were detected in 17 (85%), 18 (90%) and 19 (85%) samples respectively, out of a total of 20 samples. At 250 input copies, reads above noise level corresponding to Amplicons A, B and C were detected in 20 (100%), 19 (95%) and 20 (100%) samples respectively, out of a total of 20 samples. Hence, the analytical limit of detection, defined as the lowest detectable amount of SARS-CoV-2 RNA input at which ≥ 95% of all true positive replicates test positive, was determined to be 100 copies per reaction for Amplicon C, and 250 copies for both Amplicons A and B. Therefore, the overall analytical limit of detection of MassMark was 100 copies per reaction. To validate the clinical performance of MassMark, we performed the MassMark protocol on 22 clinical samples which had been orthogonally tested for SARS-CoV-2 with an inhouse RT- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. Out of 12 SARS-CoV-2 positive clinical samples tested, we were able to detect SARS-CoV-2 reads above the detection limit in 11 samples via MassMark (Table 1 (Table S1 ), LDX011 would approximately contain less than 100 copies of SARS-CoV-2 RNA, which is below the limit of detection of MassMark. Overall, for the 22 clinical samples tested, the concordance of SARS-CoV-2 detection compared to RT-PCR was high, with one false . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. ; https://doi.org/10.1101/2021.01.08.20249017 doi: medRxiv preprint negative only ( Table 2 ). The sensitivity of MassMark was 91.67% and specificity was 100% (Table 3 ). Mass testing has been mooted as the most practical and straightforward way 1,2 to curb the SARS-CoV-2 pandemic, as it allows health authorities to rapidly identify and isolate infectious individuals, thus limiting the spread of disease and minimizing the need for drastic widespread lockdown measures, which can have negative socioeconomic consequences 15 . Even in places which have successfully controlled the initial wave of SARS-CoV-2 infections, population-scale mass testing has been proven to be helpful in identifying asymptomatic cases 30,31 that have been missed by symptom-based detection regimes but could still contribute to silent transmission of the virus 18, 19 . With its intrinsic properties of being highly scalable and high throughput, NGS lends itself naturally to mass testing of SARS-CoV-2 as it enables a large amount of data to be generated is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. ; https://doi.org/10.1101/2021.01.08.20249017 doi: medRxiv preprint multiplexed to increase testing capacity per sequencing run. The serial pooling strategy of MassMark reduces handling complexity and conserves resources after every pooling step, thus allowing costs to be kept to a minimum, which is an important and desirable feature in the context of mass screening. Multiplex detection of three specific SARS-CoV-2 amplicons increases detection sensitivity while preserving a high level of specificity. By including multiple amplicons, the chances of encountering false negatives due to de novo mutations arising in primer binding sites are reduced, since the detection of a single amplicon is sufficient to call the sample positive. In our study, detection sensitivity is improved by integrating information from all three amplicons, compared to using any single amplicon alone (Table 1) . While RT-PCR tests are typically more sensitive than MassMark, slightly lower sensitivity is an acceptable trade-off for higher throughput in the context of mass screening and surveillance 32 . We show that MassMark is almost as sensitive as RT-PCR for detecting SARS-CoV-2 positive clinical samples with mid to late Ct values (up to Ct 33). Compared to existing methods for SARS-CoV-2 mass screening, MassMark offers a sensitivity that is several orders of magnitude higher than rapid antigen tests 33, 34 , at the cost of increased minimum assay turnaround time, though not necessarily overall throughput. The turnaround time for MassMark can be further improved by sequencing only the molecular barcodes needed for sample identification, instead of the whole amplicon. In addition, the MassMark workflow can be further streamlined by investigating its compatibility with direct, extraction-free detection of SARS-CoV-2 from patient samples, which has been extensively studied and validated with RT-PCR assays [35] [36] [37] . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. ; https://doi.org/10.1101/2021.01.08.20249017 doi: medRxiv preprint deployed on a larger scale. MassMark also allows genotyping of a limited number of hotspot regions in SARS-CoV-2, with Amplicon B designed to detect the D614G mutation, a major variant in the spike protein of SARS-CoV-2 38 . Should the need arise, other SARS-CoV-2 mutation hotspots can be potentially targeted as well by designing alternative amplicons. Since MassMark is compatible with multiplexing, the method can also be readily extended to target and differentiate other existing pathogens e.g. influenza viruses in the same assay or even novel pathogens in future pandemics. On its own, MassMark is by no means a complete solution for mass testing of SARS-CoV-2 as it requires specialized infrastructure. However, a ready source of NGS capacity is already available at existing sequencing facilities, which can potentially be repurposed in order for mass testing, which would require millions of tests per country per week 39 , to be feasible. MassMark can be part of a solution for scaling testing capacity at a centralized mass testing facility, and would have the advantage of being easily compatible with automation as well. A single benchtop sequencer has sufficient capacity to sequence > 10,000 MassMark samples in a single run (Table S2) ; with more sequencers even an average sequencing facility will be able to perform hundreds of thousands of tests in a single day. In summary, MassMark offers a unique feature set that is complementary to existing SARS-CoV-2 diagnostic methods of RT-PCR and rapid antigen tests, and would be a viable alternative option for scaling SARS-CoV-2 diagnostics especially in the context of mass screening and surveillance, which still have an important role to play in pandemic management while effective vaccines are being manufactured and made widely available. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. ; https://doi.org/10.1101/2021.01.08.20249017 doi: medRxiv preprint Clinical specimens including nasopharyngeal swabs, nasal swabs and saliva were collected as part of a study that was evaluated and approved by the Director of Medical Services, Ministry of Health, under Singapore's Infectious Diseases Act 40 . Viral nucleic acid was extracted from the specimens using Viral Nucleic Acid Extraction Kit II (Geneaid Biotech Ltd., Taiwan) according to the manufacturer's instructions. The extracted nucleic acid was stored at -20°C. Samples were processed in a College of American Pathologists (CAP) accredited and a Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory (Lucence) and archived extracted RNA from anonymized samples were used. for presence of SARS-CoV-2 RNA using N1 and N2 markers as specified in the CDC 2019- for 10 min, then an initial denaturation step at 95°C for 1 min, followed by 45 cycles of 95°C denaturation for 10s and 60°C extension for 30s. Fluorescence intensity is captured at the end of every extension cycle, and a cycle threshold (Ct) value is calculated using the Bio-Rad CFX Manager 3.1 software. Limit of detection analysis for the RT-PCR LDT is shown in Table S1 . Primers were designed against the SARS-CoV-2 Reference Genome (NC_045512.2). We is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. ; https://doi.org/10.1101/2021.01.08.20249017 doi: medRxiv preprint regions of low mutational entropy and minimize the chances of encountering mutations within the primer binding sites. Three pairs of primers were designed to capture sequences corresponding to three different target regions of SARS-CoV-2. Two of these amplicons (Amplicons A and B) are located within the S gene of SARS-CoV-2, while the remaining amplicon (Amplicon C) lies in the N gene. BLASTn analysis queries of the primer pairs used in MassMark were performed against a public domain nucleotide sequence database (updated on 07/12/2020) consisting of GenBank+EMBL+DDBJ+PDB+RefSeq sequences, but excluding EST, STS, GSS, WGS, TSA, patent sequences as well as phase 0, 1, and 2 HTGS sequences and sequences longer than 100Mb. The search parameters automatically adjust for short input sequences, with match and mismatch scores set at 1 and -3 respectively, and gap costs for creation and extension at 5 and 2 respectively. Forward primer showed high sequence homology with Pangolin coronavirus and Bat coronavirus genomes, while reverse primer showed high sequence homology with Bat coronavirus genome. Taking into account both primers, there are no significant homologies with human genome, human pathogens or human microflora that would predict potential false positive results. Both forward and reverse primers did not show significant homology with other coronaviruses. Taking into account both primers, there is no prediction of potential false positive results with human genome, human pathogens or human microflora. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. ; https://doi.org/10.1101/2021.01.08.20249017 doi: medRxiv preprint homologies with human genome, human pathogens or human microflora that would predict potential false positive results. In summary, the MassMark assay, which is designed for the specific detection of SARS-CoV-2, showed no significant combined homologies with human genome, human pathogens or human microflora that would predict potential false positive results. Reverse transcription (RT) was performed using the High-Capacity cDNA Reverse at 25°C for 10 min, followed by 37°C for 120 min and finally 85°C for 5 min. First strand cDNA products were immediately used in the subsequent steps or stored at -20°C. The spike-in control, a synthetic RNA with primer binding sites for reverse transcription and PCR primers corresponding to Amplicon A, was included in every reverse transcription reaction at 2,500 copies per well as an internal positive control. Other than the primer binding sites, the spike-in control contains a pseudo sequence which allows it to be distinguished from Amplicon A reads originating from actual SARS-CoV-2 viral RNA. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. ; https://doi.org/10.1101/2021.01.08.20249017 doi: medRxiv preprint The negative, no template controls comprised of nuclease-free water instead of extracted sample RNA. A maximum of 96 first strand cDNA samples per plate were pooled together and concentrated in an Amicon Ultra-2 Centrifugal Filter (Merck, Darmstadt, Germany), followed by a round of purification with AMPure XP beads (Beckman Coulter, Brea, CA, USA). A limited, single-cycle amplification of the pooled cDNA products using a single barcoding primer for each of the three amplicons was performed to generate double-stranded cDNA products. Briefly, 25 μl of purified first strand cDNA was mixed with 5 μl 5X SuperFi II Buffer, 1 μl 10mM dNTPs, 1 μl Platinum SuperFi II DNA (Invitrogen, Waltham, MA, USA), 1 μl 5μM barcoding (plate) forward primers (Integrated DNA Technologies) and nuclease-free water in a 50 μl reaction. Reactions were carried out in a C1000 Touch Thermal Cycler at 98°C for 90 s, 60°C for 6 min and finally 72°C for 6 min. Double-stranded cDNA products were immediately used in the subsequent steps or stored at -20°C. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 9, 2021. Samples were run with 0 copies (n=56), 100 copies (n=20) and 250 copies (n=20) of input synthetic SARS-CoV-2 RNA. Solid horizontal lines represent mean read counts. Dotted lines separate read counts obtained for replicates of 0 copies and replicates of copy number representing the LOD of MassMark assay for each of the three amplicons. The LOD differs for each amplicon and is set to 100 copies per reaction for the overall assay. NovaSeq 6000 (S1 Flow Cell) 46,000 Romer -Roadmap to Responsibly Reopen America US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome Coronavirus 2. Emerg Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States Surveillance is underestimating the burden of the COVID-19 pandemic Substantial underestimation of SARS-CoV-2 infection in the United States Ranking the effectiveness of worldwide COVID-19 government interventions Covid-19: Is a second wave hitting Europe? Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints | Pfizer Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna Articles Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy Assessment of monthly economic losses in Wuhan under the lockdown against COVID-19 Occurrence and transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: A living systematic review and meta-analysis Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis Presymptomatic Transmission of SARS-CoV-2 -Singapore Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19 COVID-19 Test Result Turnaround Time for Residents and Staff in US Nursing Homes Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening LAMP-Seq: Population-Scale COVID-19 Diagnostics Using Combinatorial Barcoding A Massively Parallel COVID-19 Diagnostic Assay for Simultaneous Testing of 19200 Patient Samples -Google Docs HiDRA-seq: High-Throughput SARS-CoV-2 Detection by RNA Barcoding and Amplicon Sequencing Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States The effectiveness of population-wide, rapid antigen test based screening in reducing SARS-CoV-2 infection prevalence in Slovakia Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China Rapid Response to an Outbreak in Qingdao Rethinking Covid-19 Test Sensitivity -A Strategy for Containment Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass community testing Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary respiratory materials Direct RT-qPCR detection of SARS-CoV-2 RNA from patient nasopharyngeal swabs without an RNA extraction step Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus The explosion of new coronavirus tests that could help to end the pandemic Infectious Diseases Act -Singapore Statutes Online Nextstrain: real-time tracking of pathogen evolution Data, disease and diplomacy: GISAID's innovative contribution to global health We would like to acknowledge Ziyi Wan and Ramandeep Virk for their support with samples and sequence analysis for primer design, and the medical laboratory technologists at Lucence service laboratory. The authors declare no competing interests.